Page last updated: 2024-11-05

lincomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3000540
CHEMBL ID1447
CHEBI ID6472
SCHEMBL ID4010
MeSH IDM0012521

Synonyms (110)

Synonym
frademicina
lincolcina
cillimycin
AB01275426-01
(2s,4r)-n-((1s)-2-hydroxy-1-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2h-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide
(2s,4r)-n-((1r,2r)-2-hydroxy-1-((2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2h-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide
bdbm50335522
1-methyl-4-propyl-pyrrolidine-2-carboxylic acid [2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide
lincomycine
CHEBI:6472 ,
lincomicina
methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-d-erythro-alpha-d-galacto-octopyranoside
methyl 6,8-dideoxy-6-({[(2s,4r)-1-methyl-4-propylpyrrolidin-2-yl]carbonyl}amino)-1-thio-d-erythro-alpha-d-galacto-octopyranoside
lincomycinum
methyl 6,8-dideoxy-6-{[(4r)-1-methyl-4-propyl-l-prolyl]amino}-1-thio-d-erythro-alpha-d-galacto-octopyranoside
einecs 205-824-6
d-erythro-alpha-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, (2s-trans)-
d-erythro-alpha-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-((((2s,4r)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-
lincomycine [french]
hsdb 3109
lincomicina [inn-spanish]
d-erythro-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-, trans-alpha-
lincomycinum [inn-latin]
lincolnensin
u 10,149a
lincomycin [usan:inn:ban]
methyl 6,8-dideoxy-6-(1-methyl-4-propyl-2-pyrrolidinecarboxamido)-1-thio-d-erythro-d-galacto-octopyranoside (alpha-form)
jiemycin
lincomycine [inn-french]
brn 0707677
d-erythro-.alpha.-d-gluco-octopyranoside, methyl 6,8-dideoxy-6-[[[(2s,4r)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-
(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide
SMP1_000178
154-21-2
C06812
lincomycin
DB01627
D00223
LCM ,
lincomycin (usan/inn)
lincomycin, (2s-cis)-isomer
HMS2089A13
CHEMBL1447 ,
u-10,149
u-10149
(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
AC1MHD7X ,
u 10149
AKOS015951392
unii-bod072yw0f
bod072yw0f ,
lincomyocin
lincorex
lincomycin [hsdb]
lincomycin [mart.]
lincomycin [vandf]
methyl 6,8-dideoxy-6-trans-(1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-d-erythro-.alpha.-d-galacto-octopyranoside
lincomycin [mi]
lincomycin [who-dd]
clindamycin hydrochloride impurity a [ip]
lincomycin [green book]
clindamycin phosphate impurity a [ep impurity]
lincomycin [inn]
lincomycin [usp impurity]
lincomycin [orange book]
clindamycin hydrochloride impurity a [ep impurity]
methyl 6,8-dideoxy-6-((((2s,4r)-1-methyl-4-propylpyrrolidin-2-yl)carbonyl)amino)-1-thio-d-erythro-.alpha.-d-galacto-octopyranoside
(2s-trans)-methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-d-erythro-.alpha.-d-galacto-octopyranoside
lincomycin [usan]
BRD-K49384696-003-01-9
CCG-208231
SCHEMBL4010
OJMMVQQUTAEWLP-KIDUDLJLSA-N
(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide
3qb ,
lincomycin, antibiotic for culture media use only
W-109518
DTXSID3023215 ,
u10149a
methyl (5r)-5-[(1r,2r)-2-hydroxy-1-{[(4r)-1-methyl-4-propyl-l-prolyl]amino}propyl]-1-thio-beta-l-arabinopyranoside
Q423428
lincomycin,(s)
(2s,4r)-n-((1r,2r)-2-hydroxy-1-((2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide
gtpl10941
l-mycin
bactramycin
u10149
HY-117660
CS-0066775
EN300-118720
linocin
Z1515385088
(2s-trans)-methyl 6,8-dideoxy-6-
lincomycin 100, lincomycin 25, lincomycin 300
lincomycin (mart.)
lincomed 300
lincomycine (inn-french)
clindamycin phosphate impurity a (ep impurity)
lincomix 20, lincomix 50
methyl 6,8-dideoxy-6-((((2s,4r)-1-methyl-4-propylpyrrolidin-2-yl)carbonyl)amino)-1-thio-d-erythro-alpha-d-galacto-octopyranoside
j01ff02
lincomycin (usp impurity)
dtxcid003215
lincomycin injectable, usp
lincomicina (inn-spanish)
d-erythro-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-(1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-, trans- alpha
lincomycin injectable 30%
u 10,1499
d-erythro-alpha-d-galacto-octopyranoside, methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, trans- alpha-
lincomycinum (inn-latin)

Research Excerpts

Toxicity

Mild to severe and persisting diarrhea and even colitis have been reported as a side effect of therapy with lincomycin and clindamycin.

ExcerptReferenceRelevance
" Severe pathologic conditions, over-dosage, or concomitant exposure to other potent drugs may predispose a patient to these acute adverse effects."( Acute adverse effects of antibiotics.
Adams, HR, 1975
)
0.25
"Mild to severe and persisting diarrhea and even colitis have been reported as a side effect of therapy with lincomycin and clindamycin."( Use of gentamicin to prevent intestinal side effects of lincomycin therapy.
Balsari, A; Cambielli, M; Evangelista, A; Fesce, E; Guslandi, M; Tittobello, A, 1978
)
0.26
" Histological examinations showed that on intravenous administration lincomycin had a low irritating effect on the vessel walls and on intramuscular administration it had an insignificant irritating effect without any signs of total toxic effect."( [Cytomorphological study of lincomycin toxicity].
Berezina, EK; Gerasimova, SS, 1977
)
0.26
"In this experimental study both biological treatability of pharmaceuticals and their potential toxic effect in biological processes were evaluated."( Biodegradability and toxicity of pharmaceuticals in biological wastewater treatment plants.
Cappai, G; Carucci, A; Piredda, M, 2006
)
0.33
" Population growth rates were assessed via epifluorescent microscopic cell counts, from which the half-max inhibitory concentrations (IC(50)) were calculated and used as part of a toxic unit (TU) method for assessing mixture interactions."( Toxic effect of the combined antibiotics ciprofloxacin, lincomycin, and tylosin on two species of marine diatoms.
Hagenbuch, IM; Pinckney, JL, 2012
)
0.38

Pharmacokinetics

The pharmacokinetic properties and bone concentrations of lincomycin in cats after single intravenous and intramuscular administrations at a dosage rate of 10 mg/kg were investigated. Our findings demonstrated that consumption of lin comycin could lead to the formation of specific metabolites and changes of ginsenoside Rb1 in the gut.

ExcerptReferenceRelevance
"Effects of altered plasma alpha-1-acid glycoprotein (AGP) levels on pharmacokinetic parameters of basic antimicrobials, erythromycin (EM), lincomycin (LM) and clindamycin (CM) were evaluated in pigs by simulation analysis."( Effects of altered plasma alpha-1-acid glycoprotein levels on pharmacokinetics of some basic antibiotics in pigs: simulation analysis.
Kuroha, M; Shimoda, M; Son, DS, 2001
)
0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The pharmacokinetic properties and bone concentrations of lincomycin in cats after single intravenous and intramuscular administrations at a dosage rate of 10 mg/kg were investigated."( Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats.
Albarellos, GA; Denamiel, GA; Landoni, MF; Montoya, L; Velo, MC, 2012
)
0.38
" Our findings demonstrated that consumption of lincomycin could lead to the formation of specific metabolites and pharmacokinetic changes of ginsenoside Rb1 in the gut, attributed to alterations in metabolic activities of intestinal bacteria."( Effects of broad-spectrum antibiotics on the metabolism and pharmacokinetics of ginsenoside Rb1: a study on rats׳ gut microflora influenced by lincomycin.
Fan, L; Li, X; Peng, Y; Wang, M; Xu, R, 2014
)
0.4
" Conclusions The methods described here meet validation acceptance criteria and were suitable for application in a pilot pharmacokinetic research study performed in a sheep model."( Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study.
Dhanani, J; Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Wallis, SC, 2020
)
0.56

Compound-Compound Interactions

Tobramycin in combination with clindamycin or lincomycin were used as systemic antibiotics in the treatment of 20 consecutive patients with septic peritonitis or intraabdominal sepsis, 10 of which were in septic shock.

ExcerptReferenceRelevance
" An investigation was therefore carried out to determine whether aztreonam, a synthetic monocyclic beta-lactam antibiotic, can safely be combined with cyclosporin."( Aztreonam can safely be used in combination with cyclosporin without aggravating nephrotoxicity.
Hoitsma, AJ; Koene, RA; Rietbroek, RC, 1989
)
0.28
"We investigated the antibacterial activity of clindamycin and lincomycin at 1/4 X minimum inhibitory concentration (MIC), 1 X MIC and 4 X MIC against a serum-resistant Staphylococcus aureus and a serum-resistant Staphylococcus epidermidis strain in broth, in serum with and without the presence of leukocytes and in Hank's medium in combination with leukocytes alone."( [Antibacterial activity of clindamycin and lincomycin in broth, serum, and in combination with polymorphonuclear leukocytes against Staphylococcus aureus and Staphylococcus epidermidis].
Bassler, M; Daschner, F; Just, HM; Richter, A; Zeller, H,
)
0.13
"Tobramycin in combination with clindamycin or lincomycin were used as systemic antibiotics in the treatment of 20 consecutive patients with septic peritonitis or intraabdominal sepsis, 10 of which were in septic shock."( High-dose tobramycin combined with clindamycin or lincomycin in the treatment of septic peritonitis and intraabdominal sepsis.
Edén, T; Muth, L, 1981
)
0.26
" Our purpose was to investigate the clinical efficacy of topical application of LM and LA in combination with betamethasone valerate (BV) in melasma patients."( Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients.
Ha, DJ; Kim, HJ; Kim, HY; Lee, MH; Paik, JH, 2002
)
0.31
"A method for the quantification of clindamycin in animal plasma using high-performance liquid chromatography combined with electrospray ionization mass spectrometry (LC/ESI-MS/MS) is presented."( Determination of clindamycin in animal plasma by high-performance liquid chromatography combined with electrospray ionization mass spectrometry.
Cherlet, M; Croubels, S; De Backer, P, 2002
)
0.31

Bioavailability

The absorption rate of [14C]-taurocholic acid was measured in untreated rats and rats treated with lincomycin using an in vivo perfusion technique. Therefore, manure-derived biochars had lasting lin comycin sequestration capacity.

ExcerptReferenceRelevance
" To find whether the watery diarrhoea was due to bile acid malabsorption, the absorption rate of [14C]-taurocholic acid was measured in untreated rats and rats treated with lincomycin using an in vivo perfusion technique."( The mechanism of lincomycin-induced diarrhoea.
Andersen, KJ; Hoff, SG; Schjonsby, H, 1977
)
0.26
" This difference is attributed to differences in bioavailability and/or binding characteristics of the drugs for bioreceptors, as a consequence of structural modifications in the drug molecules, and to differences in modes of action in the respective organisms."( Microbial kinetics of drug action against gram-positive and gram-negative organisms. III: Effect of lincomycin and clindamycin combinations on Staphylococcus aureus and Escherichia coli.
Heman-Ackah, SM, 1975
)
0.25
" Unlike morphine, the glucuronide conjugate in bile was poorly absorbed from the small intestine where its hydrolysis occurred slowly."( Studies of the enterohepatic circulation of morphine in the rat.
Levine, RR; Walsh, CT, 1975
)
0.25
" For both compounds the bioavailability was strongly dependent on the presence of food in the gastrointestinal tract."( Bioavailability of spiramycin and lincomycin after oral administration to fed and fasted pigs.
Gyrd-Hansen, N; Nielsen, P, 1998
)
0.3
" Therefore, manure-derived biochars had lasting lincomycin sequestration capacity, implying that biochar soil amendment could significantly affect the distribution, transport, and bioavailability of lincomycin in agroecosystems."( Sorption of Lincomycin by Manure-Derived Biochars from Water.
Boyd, SA; Chuang, YH; Gonzalez, JM; Johnston, CT; Lehmann, J; Li, H; Liu, CH; Teppen, BJ; Zhang, W, 2016
)
0.43

Dosage Studied

lincomycin was mixed into a barley pellet and fed to 3,000 range ewes at a dosage of 225 mg/ewe/day. The plants were cropped in loamy clay soil dosed at 140 kg total N/ha and containing antibiotics. In this study, a lab-scale incubation experiment was conducted to investigate the influence of the amendment dosage.

ExcerptRelevanceReference
"Serum concentrations of drug were obtained at various times after intramuscular dosing of healthy mice with either clindamycin or lincomycin hydrochlorides."( Serum and peritoneal fluid concentrations of clindamycin and lincomycin in the mouse.
Brookes, LG; Dempsey, G; Kanwar, RS; Rosen, A, 1979
)
0.26
" Up to this time, amoxicillin has not been commercially available as an injectable dosage form."( Pneumococcal meningitis-therapeutic studies in mice.
Hirth, RS; Price, KE; Tsai, YH; Williams, EB, 1975
)
0.25
" Rabbits that had been deprived of food before being dosed had a reduced gastric pH and a reduced response to the enterotoxin."( Assay of the heat-labile enterotoxin of Escherichia coli in infant rabbits.
Burgess, MN; Cowley, CM; Melling, J; Mullan, NA; Newsome, PM, 1979
)
0.26
" Varying the pH of the dosing solution did not change ocular absorption and distribution substantially."( Intraocular penetration of topically applied lincomycin hydrochloride in rabbits.
Anderson, JA; Dea, FJ; Kleinberg, J; Leopold, IH, 1979
)
0.26
" Inhibition by clindamycin demonstrated a gradual dose-response curve, with inhibition first noted at about 20 microgram of antibiotic/ml and maximal inhibition at 1,000 microgram/ml."( Effect ob broad-spectrum antibiotics on in vitro synthesis of DNA in the rabbit colon.
Alpers, DH; Grimme, N, 1978
)
0.26
"0 mug/ml with a standard dosage regimen of approximately 5 mg/kg per day."( Tobramycin in pediatric use.
McAllister, TA; Raine, PA; Tait, SC; Young, DG, 1976
)
0.26
" The combined action of the mixtures can be quantitatively predicted from the separate dose-response curves of either component drug alone."( Microbial kinetics of drug action against gram-positive and gram-negative organisms. III: Effect of lincomycin and clindamycin combinations on Staphylococcus aureus and Escherichia coli.
Heman-Ackah, SM, 1975
)
0.25
" On the other hand, lincomycin shows excellent penetration into body fluids and tissues and its dosage can be adapted to actual clinical situation in a very wide range."( [Lincosamide antibiotics].
Vacek, V, 1991
)
0.28
"Because of an episode of abortion caused by a tetracycline-resistant Campylobacter jejuni, lincomycin was mixed into a barley pellet and fed to 3,000 range ewes at a dosage of 225 mg/ewe/day."( Losses related to the ingestion of lincomycin-medicated feed in a range sheep flock.
Bulgin, MS, 1988
)
0.27
" Dosage adjustments would not be required for the antibiotics tylosin or lincomycin when given to newborn calves, but may be necessary for chloramphenicol given to calves before they are 4 to 6 weeks old."( Comparative pharmacokinetics of antibiotics in newborn calves: chloramphenicol, lincomycin, and tylosin.
Barto, PB; Burrows, GE; Martin, B; Tripp, ML, 1983
)
0.27
" This indicates that enhanced gene dosage is one of the factors for the overproduction of LM and demonstrates that large-scale genome rearrangements can be a result of classical strain improvement by mutagenesis."( Molecular characterization of the lincomycin-production gene cluster of Streptomyces lincolnensis 78-11.
Peschke, U; Piepersberg, W; Schmidt, H; Zhang, HZ, 1995
)
0.29
" These results suggested that adjustment of dosage regimen of EM and CM is required in pathophysiological conditions, but that of LM is not required."( Effects of altered plasma alpha-1-acid glycoprotein levels on pharmacokinetics of some basic antibiotics in pigs: simulation analysis.
Kuroha, M; Shimoda, M; Son, DS, 2001
)
0.31
" Loose stools and diarrhea were frequently encountered but these symptoms abated when the dosage was reduced."( LINCOMYCIN IN DERMATOLOGIC PRACTICE.
KANEE, B, 1965
)
0.24
" The applied dosage was often lower than suggested in the literature."( [The use of macrolides, lincomycin and tiamulin as animal feed drugs for pigs in Schleswig-Holstein].
Bettin, U; Broll, S; Kietzmann, M; Kreienbrock, L,
)
0.13
" Anaerobic microcosms, prepared from freshly collected lagoon slurries, were amended with individual antibiotics at 10 mg/L for the initial screening study and at 1, 5, and 25 mg/L for the dose-response study."( Inhibition of microbial metabolism in anaerobic lagoons by selected sulfonamides, tetracyclines, lincomycin, and tylosin tartrate.
Adams, CD; Henny, C; Loftin, KA; Mormile, MR; Surampali, R, 2005
)
0.33
" The assay was shown to be specific for clindamycin, several impurities, and triethyl citrate, a retained excipient that was present in the dosage form."( Development and validation of a gradient HPLC method for the determination of clindamycin and related compounds in a novel tablet formulation.
Platzer, DJ; White, BA, 2006
)
0.33
"The pharmacokinetic properties and bone concentrations of lincomycin in cats after single intravenous and intramuscular administrations at a dosage rate of 10 mg/kg were investigated."( Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats.
Albarellos, GA; Denamiel, GA; Landoni, MF; Montoya, L; Velo, MC, 2012
)
0.38
" Favourable pharmacokinetic profile in buffalo calves and a convenient dosing interval suggest that lincomycin may be an appropriate antibacterial in buffalo species for gram-positive and anaerobic bacterial pathogens susceptible to lincomycin."( Pharmacokinetics of lincomycin following single intravenous administration in buffalo calves.
Dumka, VK; Sreeshitha Gouri, S; Venkatachalam, D, 2014
)
0.4
" Our results indicate that lincomycin at subinhibitory concentrations potentiates the production of secondary metabolites in Streptomyces strains and suggest that activating these strains by utilizing the dose-response effects of lincomycin could be used to effectively induce the production of cryptic secondary metabolites."( Lincomycin at Subinhibitory Concentrations Potentiates Secondary Metabolite Production by Streptomyces spp.
Hosaka, T; Imai, Y; Ochi, K; Sato, S; Tanaka, Y, 2015
)
0.42
" The influences of dosage of EDC/NHS and concentration of O-CMCS on the swelling properties of the hydrogels were investigated."( Preparation and antibacterial properties of O-carboxymethyl chitosan/lincomycin hydrogels.
Cai, W; Chen, X; He, G; Ke, W; Kong, Y; Yin, Y; Zheng, H, 2016
)
0.43
" In this study, a lab-scale incubation experiment was conducted to investigate the influence of the amendment dosage on lincomycin resistance genes and soil bacterial communities via quantitative PCR and 16S rRNA sequencing."( Dosage effects of lincomycin mycelial residues on lincomycin resistance genes and soil microbial communities.
Dai, X; Liu, H; Wang, M, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
carbohydrate-containing antibioticAny carbohydrate derivative that exhibits antibiotic activity.
S-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and a S atom bound to a carbon atom, thus creating a C-S bond.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
pyrrolidinecarboxamide
L-proline derivativeA proteinogenic amino acid derivative resulting from reaction of L-proline at the amino group or the carboxy group, or from the replacement of any hydrogen of L-proline by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serum paraoxonase/arylesterase 1Homo sapiens (human)Ki18,300.00009.00009.00009.0000AID1803291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)Kd12.00000.08933.31358.0000AID557095
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
negative regulation of plasma lipoprotein oxidationSerum paraoxonase/arylesterase 1Homo sapiens (human)
cholesterol metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
response to toxic substanceSerum paraoxonase/arylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxSerum paraoxonase/arylesterase 1Homo sapiens (human)
carboxylic acid catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
organophosphate catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
phosphatidylcholine metabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
lactone catabolic processSerum paraoxonase/arylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
aryldialkylphosphatase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
arylesterase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
calcium ion bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
phospholipid bindingSerum paraoxonase/arylesterase 1Homo sapiens (human)
protein homodimerization activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activitySerum paraoxonase/arylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
extracellular regionSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
endoplasmic reticulum membraneSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular exosomeSerum paraoxonase/arylesterase 1Homo sapiens (human)
blood microparticleSerum paraoxonase/arylesterase 1Homo sapiens (human)
high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
spherical high-density lipoprotein particleSerum paraoxonase/arylesterase 1Homo sapiens (human)
extracellular spaceSerum paraoxonase/arylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (155)

Assay IDTitleYearJournalArticle
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID584114Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID150906The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Pseudomonas aeruginosa at the Upjohn culture 951993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID64053The compound was tested for inhibition of Polyphenylalanine synthesis with hybrid antibiotics in Escherichia coli ribosome system at concentration of at 1*10e-5 M1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID396001Antimicrobial activity against Mycoplasma putrefaciens Jordanian isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID540928Antimicrobial activity against streptomycin-resistant Streptomyces coelicolor KO-178 harboring rpsL K88E mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID533663Antimicrobial activity against Staphylococcus aureus RN10242008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID1241208Inhibition of pre-miR-21 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID495940Antimicrobial activity against lincomycin resistant Staphylococcus epidermidis isolate 102OL harboring lnuA gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID533662Antimicrobial activity against Staphylococcus aureus RN4220 harboring vgaAv positive plasmid CU12008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID396000Antimicrobial activity against Mycoplasma putrefaciens French isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID495945Antimicrobial activity against erythromycin, lincomycin resistant Staphylococcus haemolyticus isolate 113OL harboring msrA lnuA gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID495942Antimicrobial activity against erythromycin resistant Staphylococcus epidermidis isolate 129OV harboring msrA gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID1879067Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID198185The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Streptococcus pneumoniae at the Upjohn culture1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID520084Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1241209Binding affinity to 5'-FAM-pre-miR-372 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID533659Antimicrobial activity against Staphylococcus aureus RN42202008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID1879068Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method2022European journal of medicinal chemistry, Mar-05, Volume: 231Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
AID557096Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID540931Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP1 harboring rpsL A262G and C271T mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID560250Antibacterial activity against Staphylococcus aureus RN4220 harboring aadD and tet(L) gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID540932Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor SP2 harboring rpsL K88E mutant gene and inserted glycine at position 92 of the gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID534107Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID520082Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID584116Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP722010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1241207Inhibition of pre-miR-373 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID533660Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid VGA2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID278858Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID495946Antimicrobial activity against erythromycin, lincomycin, clindamycin resistant Staphylococcus epidermidis isolate 32OL harboring msrA lnuA vgaALC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID278860Antiproliferative effect against HeLa cells after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID560247Antibacterial activity against Staphylococcus aureus RN4220 by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID557092Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1241205Inhibition of pre-miR-372 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID285159Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1241211Binding affinity to 5'-FAM-pre-miR-373 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID534112Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm19802008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1241206Inhibition of pre-miR-17 (unknown origin) cleavage assessed as reduction of oncogenic microRNAs biogenesis by measuring fluorescence every minute for 5 hrs using 5'-FAM,3'-dabcyl-pre-miRNA beacons by FRET assay in presence of recombinant Dicer2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID495947Antimicrobial activity against Staphylococcus aureus isolate CIP 107907 harboring vgaA gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID495936Antimicrobial activity against erythromycin, inducible lincomycin, inducible clindamycin resistant Staphylococcus haemolyticus isolate 31UL harboring ermC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID495948Antimicrobial activity against Staphylococcus aureus ATCC 29213 incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID278856Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID495939Antimicrobial activity against lincomycin resistant Staphylococcus haemolyticus isolate 123PL harboring lnuA gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID534109Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm05272008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID495944Antimicrobial activity against erythromycin, lincomycin, clindamycin resistant Staphylococcus epidermidis isolate 1036UL harboring ermC vgaALC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID540929Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor KO-347 harboring rpsl P91S mutant gene after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID64052The compound was tested for inhibition of Polyphenylalanine synthesis with hybrid antibiotics in Escherichia coli ribosome system at concentration of at 1*10e-3 M1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID150905The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Pseudomonas aeruginosa at the Upjohn culture 66761993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID534106Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID197845The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in staphylococcus aureus at the Upjohn culture 66851993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID533665Antimicrobial activity against Staphylococcus aureus ATCC 292132008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID534110Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID197846The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in staphylococcus aureus at the Upjohn culture 66901993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID534108Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID278859Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID495943Antimicrobial activity against erythromycin, lincomycin, clindamycin resistant Staphylococcus haemolyticus isolate 65OL harboring ermC vgaALC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540927Antimicrobial activity against Streptomyces coelicolor 1147 after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID560248Antibacterial activity against Staphylococcus aureus RN4220 harboring aadD, tet(L), dfrK and vga(C) gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID285160Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID495941Antimicrobial activity against erythromycin resistant Staphylococcus haemolyticus isolate 202BB harboring msrA gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID557102Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 130 to 180 ug/ml by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID64258The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Enterococcus faecalis at the Upjohn culture1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID278861Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID495937Antimicrobial activity against erythromycin, inducible lincomycin, inducible clindamycin resistant Staphylococcus epidermidis isolate 32PL harboring ermC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID534111Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Characterization of TolC efflux pump proteins from Pasteurella multocida.
AID557097Protein binding in serum2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID520087Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID278857Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
AID584115Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID519833Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID557093Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID520083Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID533661Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid CU12008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID495938Antimicrobial activity against lincomycin, clindamycin resistant Staphylococcus haemolyticus isolate 29OL harboring vgaALC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID285161Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID285162Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID197847The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in staphylococcus aureus at the Upjohn culture 761993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID64073The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Escherichia coli at the Upjohn culture1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID540930Antimicrobial activity against paromomycin-resistant Streptomyces coelicolor 92G harboring rpsL gene with inserted glycine at position 92 after 48 hrs2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
A novel insertion mutation in Streptomyces coelicolor ribosomal S12 protein results in paromomycin resistance and antibiotic overproduction.
AID198324The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Salmonella schottmuelleri1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID557091Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID495935Antimicrobial activity against erythromycin, lincomycin, clindamycin resistant Staphylococcus epidermidis isolate 44KR harboring ermC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID557094Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID396002Antimicrobial activity against Mycoplasma putrefaciens KS1 after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID557090Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID519834Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID520086Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID560249Antibacterial activity against Staphylococcus aureus RN4220 harboring tet(L), dfrK gene by CLSI method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Novel ABC transporter gene, vga(C), located on a multiresistance plasmid from a porcine methicillin-resistant Staphylococcus aureus ST398 strain.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID495934Antimicrobial activity against erythromycin, lincomycin, clindamycin resistant Staphylococcus haemolyticus isolate 134PL harboring ermC gene incubated at 37 degC for 24 hrs by agar diffusion method2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID520081Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID94132The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Klebsiella pneumoniae at the Upjohn culture1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID520085Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID520088Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Role of the AheABC efflux pump in Aeromonas hydrophila intrinsic multidrug resistance.
AID557095Binding affinity to first site on human serum albumin by SPR2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID198315The compound was tested for minimum inhibitory concentration required for inhibition of microbial growth in Streptococcus pyogenes at the Upjohn culture1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID64049The compound was tested for inhibition of Polyphenylalanine synthesis with hybrid antibiotics in Escherichia coli ribosome system at concentration of 1*10e-4 M1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID1241210Binding affinity to 5'-FAM-pre-miR-17 (unknown origin) after 4 hrs by fluorescence assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Ribosome-targeting antibiotics as inhibitors of oncogenic microRNAs biogenesis: Old scaffolds for new perspectives in RNA targeting.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID64050The compound was tested for inhibition of Polyphenylalanine synthesis with hybrid antibiotics in Escherichia coli ribosome system at concentration of 1*10e-6 M1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID533664Antimicrobial activity against Staphylococcus aureus RN1024-tms2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1803291PON Activity Assay from Article 10.3109/14756366.2012.681653: \\Impacts of some antibiotics on human serum paraoxonase 1 activity.\\2013Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 28, Issue:4
Impacts of some antibiotics on human serum paraoxonase 1 activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901558 (73.66)18.7374
1990's133 (6.29)18.2507
2000's154 (7.28)29.6817
2010's177 (8.37)24.3611
2020's93 (4.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials108 (4.84%)5.53%
Reviews112 (5.02%)6.00%
Case Studies102 (4.57%)4.05%
Observational0 (0.00%)0.25%
Other1,911 (85.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule 500 Mg Formulations, In Healthy Volunteers Using Formulations (Frademicina®) Manufactured By Pfizer Laboratories Ltd [NCT01058824]Phase 136 participants (Actual)Interventional2009-04-30Completed
Development of a Serum and Cellular Biomarkers Cluster for the Assessment of Degenerative Aortic Valve Stenosis Progression. [NCT04312139]280 participants (Anticipated)Observational2020-03-01Recruiting
Staphylococcus Aureus Network Adaptive Platform Trial [NCT05137119]Phase 46,000 participants (Anticipated)Interventional2022-02-16Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]